Medical News & Research

In a multicenter retrospective cohort of 558,823 transfusions, allergic reactions were nearly 4-fold higher in US high-prevalence regions when type O patients received B or AB units vs O units, supporting targeted mitigation in these settings.

In the phase 3 randomized MAIA trial of 737 patients with 7.5 years median follow-up, D-Rd improved median OS to 90.3 vs 64.1 months with Rd alone and delayed subsequent therapy initiation.

In a single-center observational cohort of 104 recipients, overall CHIP did not track with CRS or ICANS, but TP53-mutant CHIP correlated with baseline cytopenias, reduced CAR T expansion, and worse outcomes, supporting genotype-directed monitoring.

In a prospective citywide NICU/PICU program of 100 patients, median turnaround was 3.4 days with 53% diagnostic yield and 53% management change, outperforming a matched historical cohort with 38-day turnaround and 30% yield.